LY3556050 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis
Conditions
Osteoarthritis
Trial Timeline
Nov 12, 2020 → Oct 21, 2021
NCT ID
NCT04627038About LY3556050 + Placebo
LY3556050 + Placebo is a phase 2 stage product being developed by Eli Lilly for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04627038. Target conditions include Osteoarthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06074562 | Phase 2 | Completed |
| NCT04874636 | Phase 2 | Completed |
| NCT04707157 | Phase 2 | Terminated |
| NCT04627038 | Phase 2 | Completed |
| NCT05341102 | Phase 1 | Completed |
Competing Products
20 competing products in Osteoarthritis